+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Torisel (temsirolimus; Pfizer) Drug Overview 2019

  • ID: 4846107
  • Report
  • 24 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Torisel (temsirolimus; Pfizer) is an inhibitor of mammalian target of rapamycin (mTOR), which is an intracellular protein that has been implicated in multiple growth-related cellular functions. Torisel works by binding to an intracellular protein, FKBP12, and the protein-drug complex inhibits the activity of mTOR. The inhibition of mTOR prevents the transcription of mRNAs and translation of proteins required for cell cycle progression from G1 to S phase.

Analyst Outlook
Torisel (temsirolimus; Pfizer) has been relatively successful in the renal cell carcinoma (RCC) market even though its sales have never reached those of Pfizer’s other RCC staples Inlyta (axitinib) and Sutent (sunitinib). Due to the lack of development of Torisel in combination with a programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) therapy, it is forecast to lose patient share to a range of more efficacious combination therapies expected to be approved for the first-line treatment of RCC. Pfizer will aim to protect its share of first-line patients by promoting the use of Inlyta, which is being investigated in combination with both Bavencio (avelumab; Merck KGaA/Pfizer) and Keytruda (pembrolizumab; Merck & Co). Torisel is expected to experience significant generic erosion with key patents expiring in August 2019 (US), February 2020 (Japan), and March 2020 (EU), while Inlyta’s patents do not expire until 2025
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
  • Drug Overview
  • Product Profiles
  • Torisel: Renal cell carcinoma (RCC)
  • Torisel: NHL: Mantle cell lymphoma (MCL)
LIST OF FIGURES
Figure 1: Torisel for RCC – SWOT analysis
Figure 2: The author's drug assessment summary of Torisel for RCC
Figure 3: The author's drug assessment summary of Torisel for RCC
Figure 4: Torisel sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Torisel for mantle cell lymphoma – SWOT analysis
Figure 6: The author's drug assessment summary of Torisel in mantle cell lymphoma
Figure 7: The author's drug assessment summary of Torisel in mantle cell lymphoma

LIST OF TABLES
Table 1: Torisel drug profile
Table 2: Torisel pivotal trial data in RCC
Table 3: Torisel Phase III data in RCC
Table 4: Torisel sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 5: Torisel drug profile
Table 6: Torisel pivotal trial data in mantle cell lymphoma
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll